Skip to Main content Skip to Navigation
Journal articles

Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir)

N. Ganne-Carrié 1, 2 R. Layese 3 V. Bourcier 2 C. Cagnot 4 P. Marcellin 5 D. Guyader 6, 7 Stanislas Pol 8, 9 D. Larrey 10 V. Lédinghen 11 D. Ouzan 12 F. Zoulim 13, 14 D. Roulot 15 A. Tran 16, 17 J.-P. Bronowicki 18 J.-P. Zarski 19 G. Riachi 20 P. Calès 21 J.-M. Péron 22 L. Alric 23 M. Bourlière 24 P. Mathurin 25 J.-F. Blanc 26 A. Abergel 27 L. Serfaty 28 A. Mallat 29 J.-D. Grangé 30 P. Attali 31 Y. Bacq 32 C. Wartelle 33 T. Dao 34 Y. Benhamou 35 C. Pilette 36 C. Silvain 37 C. Christidis 38 D. Capron 39 B. Bernard-Chabert 40 D. Zucman 41 V. Di Martino 42 J.-C. Trinchet 1, 2 P. Nahon 1, 2 F. Roudot-Thoraval 3
Abstract : Unlabelled - The aim of this work was to develop an individualized score for predicting hepatocellular carcinoma (HCC) in patients with hepatitis C (HCV)-compensated cirrhosis. Among 1,323 patients with HCV cirrhosis enrolled in the French prospective ANRS CO12 CirVir cohort, 720 and 360 were randomly assigned to training and validation sets, respectively. Cox's multivariate model was used to predict HCC, after which a nomogram was computed to assess individualized risk. During follow-up (median, 51.0 months), 103 and 39 patients developed HCC in the training and validation sets, respectively. Five variables were independently associated with occurrence of HCC: age > 50 years (hazard ratio [HR], 1.94; 95% confidence interval [CI], 1.16; 3.25; P = 0.012); past excessive alcohol intake (HR, 1.55; 95% CI, 1.02; 2.36; P = 0.041); low platelet count (<100 Giga/mm(3) : HR, 2.70; 95% CI, 1.62; 4.51; P < 0.001; [100; 150] Giga/mm(3) : HR, 1.87; 95% CI, 1.10; 3.18; P = 0.021); gamma-glutamyl transpeptidase above the upper limit of normal (HR, 1.96; 95% CI, 1.11; 3.47; P = 0.021); and absence of a sustained virological response during follow-up (HR, 3.02; 95% CI, 1.67; 5.48; P < 0.001). An 11-point risk score was derived from the training cohort and validated in the validation set. Based on this score, the population was stratified into three groups, in which HCC development gradually increased, from 0% to 30.1% at 5 years for patients with the lowest (≤3) and highest (≥8) scores (P < 0.001). Using this score, a nomogram was built enabling individualized prediction of HCC occurrence at 1, 3, and 5 years. Conclusion - This HCC score can accurately predict HCC at an individual level in French patients with HCV cirrhosis. (Hepatology 2016;64:1136-1147).
Complete list of metadatas

Cited literature [23 references]  Display  Hide  Download

https://hal-univ-rennes1.archives-ouvertes.fr/hal-01381662
Contributor : Laurent Jonchère <>
Submitted on : Wednesday, October 26, 2016 - 10:07:32 AM
Last modification on : Sunday, October 25, 2020 - 7:05:33 AM

File

Nomogram for indiv - HEP-16-02...
Files produced by the author(s)

Identifiers

Citation

N. Ganne-Carrié, R. Layese, V. Bourcier, C. Cagnot, P. Marcellin, et al.. Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir). Hepatology, Wiley-Blackwell, 2016, 64 (4), pp.1136-1147. ⟨10.1002/hep.28702⟩. ⟨hal-01381662⟩

Share

Metrics

Record views

1338

Files downloads

1304